Krishnaswamy Yeleswaram is Chief Development Officer at Rapport Therapeutics, Inc. (RAPP). They have made 1 open-market trade across 1 company since 2025, most recently 2026-08-25.
CIK 0002022156
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RAPP | 195,862 | $5.4M |
Shares reported on the most recent Form 4, priced at the 2026-08-26 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RAPP | SELL · 10b5-1 | 2026-08-24 | 2026-08-26 | $50.47 | $2.5M | -11.4% | -34.7% | — |
| RAPP | SELL · 10b5-1 | 2026-08-19 | 2026-08-20 | $49.90 | $20K | +1.0% | -17.6% | — |
| RAPP | SELL · 10b5-1 | 2026-04-17 | 2026-04-21 | $39.99 | $809K | -9.4% | -2.1% | +7.8% |
| RAPP | SELL · 10b5-1 | 2026-04-10 | 2026-04-14 | $35.03 | $696K | +1.8% | +5.7% | +13.1% |
| RAPP | SELL · 10b5-1 | 2026-04-08 | 2026-04-09 | $34.90 | $13K | +5.6% | +10.0% | +20.0% |
| RAPP | SELL · 10b5-1 | 2026-03-25 | 2026-03-26 | $29.99 | $607K | +17.8% | +23.8% | +39.8% |
| RAPP | SELL | 2025-12-31 | 2026-01-05 | $30.05 | $85K | -2.8% | -4.4% | +17.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.